Company intelligence / Profile preview

Cordex Pharma

La Jolla, California, United Statescordexbio.com ↗

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Cordex Pharma developed cardiovascular drugs based on ATP and NO pharmacology. Its lead candidate, ATPace, reached Phase 3 trials for paroxysmal supraventricular tachycardia around 2009. Another candidate, CDP-1050, was in Phase 2 development for heart failure at that time. The company also had a preclinical program targeting chronic obstructive pulmonary disease via a novel pathway[5]. No recent clinical results are available.

Therapeutic areas: PulmonologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

adenosine 5'-triphosphate

1 more asset in the full pipeline.

Request access →

Partnerships

Cato BioVentures/Cato Research – strategic master services agreement focused on regulatory and clinical oversight for pivotal trials

Beyond the preview

Go deeper on Cordex Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cordex Pharma.

Explore the full profile